Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Niemann Pick Disease

September 21, 2023 CD as API / CD derivatives / Pharma applications / Uncategorized

Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment

Cyclodextrins (CDs), the therapeutic candidates for Niemann–Pick disease type C (NPC), function dually as a shuttle and sink that catalytically

Continue reading

July 25, 2023 CD as API / Pharma applications

Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) in Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial

Niemann-Pick disease type C (NPC) is a rare, fatal, pan-ethnic, autosomal recessive lysosomal storage disease characterized by progressive major organ

Continue reading

July 21, 2023 CD as API / Pharma applications

Remembering Dr. David Begley

With immense sadness we have to announce that an outstanding Scientist, Dr. David Begley passed away on Thursday 6th July

Continue reading

April 21, 2023 CD as API / Pharma applications

The review article ‘Molecular Mind Games’ describes the latest developments in cyclodextrin research for the treatment of brain disorders

The human brain is a complex and intricate network of cells and molecules that control every aspect of our behaviour

Continue reading

April 14, 2023 CD as API / CD derivatives / Pharma applications

Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing

Core–shell superparamagnetic iron oxide nanoparticles hold great promise as a theranostic platform in biological systems. Herein, we report the biological

Continue reading

December 1, 2022 CD as API / Pharma applications

Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?

In this review, based on 250 references, the general chemical principles of direct cyclodextrin–protein interactions are summarized and highlighted, through

Continue reading

October 11, 2022 CD as API / Pharma applications

Inclusion Solves Insolubility ―Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C

Cyclodextrins (CDs) are used not only as pharmaceutical excipients but also as active pharmaceutical ingredients. CDs can act as artificial

Continue reading

October 5, 2022 CD as API / CD derivatives

Monosubstituted Maltosyl Cyclodextrins for the Potential Treatment of NPC

Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it

Continue reading

August 3, 2022 CD as API / Pharma applications

HPaCD against Alzheimer Disease

HP-beta-cyclodextrin (HPbCD) is currently in clinical trials against Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease (AD) and these trials

Continue reading

July 12, 2022 CD as API / Events / Pharma applications

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator

Continue reading

Posts navigation

1 2 3 … 6 Next Posts»

Recent Posts

  • Cyclodextrin related patent application of 2023 Nobel laureate Katalin Karikó
  • Cyclodextrin in Vaccines
  • Special Issue “New Advances in Green Extraction Technology for Natural Products”
  • Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis
  • Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins

Tags

alpha-CD Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food Gilead HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (17)
  • Analysis (39)
  • CD as API (229)
  • CD derivatives (287)
  • Cosmetics and toilettry (22)
  • Diagnosis (2)
  • Drug delivery (499)
  • E-ducation (59)
  • Environmental (84)
  • Events (167)
  • Food (138)
  • Gene delivery (12)
  • In Hungarian (4)
  • Life sciences (21)
  • Non-pharma applications (250)
  • Other industrial use (74)
  • Pharma applications (783)
  • Supramolecular systems (30)
  • Uncategorized (56)

Top Posts

  • Cyclodextrin in Vaccines
  • BioNTech's new invention: CD as potential cryoprotectant in lipid-based RNA formulation
  • Ex Vivo Drug Screening Assay with Artificial Membranes: Characterizing Cholesterol Desorbing Competencies of Beta-Cyclodextrins
  • Australian company pioneering Cavadextrin for regression of atherosclerosis
  • Cyclodextrin related patent application of 2023 Nobel laureate Katalin Karikó
  • Lanosterol eye drops for cataract treatment
  • Ashland webinar — the magic rings: how cyclodextrins can enable drug development
  • How air fresheners work?
  • Curcumin/amphiphilic cyclodextrin nanoassemblies: Theoretical andspectroscopic studies to address their debut in anticancer therapy
  • HPBCD in an approved non-replicating adenoviral vector-based gene therapy product

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 565 other subscribers
 

Loading Comments...